Oxford University coronavirus vaccine to begin human trials on Thursday as U.K. ‘throws everything’ at vital breakthrough

- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -

A coronavirus vaccine being developed by Oxford University will enter human trials as early as this Thursday, according to the U.K.’s health secretary.

The U.K. government will provide £20 million ($24 million) to the university’s team and a further £22.5 million to Imperial College, where scientists are also working on a vaccine. Scientists at Oxford have previously said the aim is to produce a million doses of the vaccine by September.

Secretary of State for Health and Social Care Matt Hancock praised both teams for making “rapid progress” and said the U.K. will throw “everything we’ve got” at developing a vaccine.

He also said the government would invest in manufacturing capabilities so that if either vaccine was successful it could be available for British people “as soon as humanly possible.”

“We are going to back them to the hilt and give them every resource that they need to get the best possible chance of success as soon as possible. The upside of being the first country in the world to develop a successful vaccine is so huge that I am throwing everything at it.”

Read:These 21 companies are working on coronavirus treatments or vaccines

However, he insisted vaccine development was a “process of trial and error and trial again.”

The Oxford University project, a collaboration between the university’s Jenner Institute and Oxford Vaccine Group, opened recruitment for the clinical trial — for healthy adults between 18 and 55 — at the end of March, having begun research on a vaccine against the coronavirus-borne disease COVID-19 in February. Trials will now begin as soon as this Thursday, the health secretary revealed in the government’s daily briefing on Tuesday.

Praising the team, Hancock said reaching this stage in normal times would “take years.”

Also:GSK, Sanofi to team up on COVID-19 vaccine

Speaking at the end of March, Adrian Hill, director of Oxford University’s Jenner Institute, said: “The Oxford team had exceptional experience of a rapid vaccine response, such as to the Ebola outbreak in West Africa in 2014. This is an even greater challenge.

“Vaccines are being designed from scratch and progressed at an unprecedented rate. The upcoming trial will be critical for assessing the feasibility of vaccination against COVID-19 and could lead to early deployment.”

Read on:Hydroxychloroquine as treatment for COVID-19 shows no benefit and more deaths in VA study

Originally Published on MarketWatch

 

Home of Science
Follow me

Latest posts by Home of Science (see all)
- Advertisement -

Discover

Sponsor

Latest

US automakers, set to reopen factories Monday, wait and watch on word from Mexico

KEY POINTS Mexico is expected to delay the restart of its “essential” manufacturing operations, including automotive, until June 1. The delay, according to federal...

The Truth About Online Schools

The truth is, the Internet has a huge number of options for anyone who wants to learn about the online education option. There are...

Opinion: This one niche of the sagging real estate market is growing rapidly

The response to the novel coronavirus is adding a twist to the real estate adage that it’s all about location, location, location. Even before the...

Apple Will Host a Virtual Worldwide Developer Conference on June 22

Apple (NASDAQ: AAPL) announced today that it plans to host its Worldwide Developers Conference (WWDC) as a virtual event this year beginning on June 22. Developers...

Hot Shows of 2020

If you want to get a good look at the hottest shows of the future, then look no further than the 2020 holiday season....
Home of Science
Follow me
Latest posts by Home of Science (see all)